Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $860.27 | 5 | 61.5% |
| Food and Beverage | $336.98 | 7 | 24.1% |
| Unspecified | $202.26 | 1 | 14.5% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $1,184 | 11 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $202.26 | 1 | $0 (2022) |
| AbbVie, Inc. | $12.90 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $202.26 | 1 | Regeneron Pharmaceuticals, Inc. ($202.26) |
| 2019 | $1,184 | 11 | Merck Sharp & Dohme Corporation ($1,184) |
| 2017 | $12.90 | 1 | AbbVie, Inc. ($12.90) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/01/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $202.26 | Research |
| Study: A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | ||||||
| 09/14/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $166.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/14/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | Cash or cash equivalent | $24.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $166.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | Cash or cash equivalent | $57.18 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $54.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $52.18 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $44.35 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $264.52 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $166.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | Cash or cash equivalent | $94.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $91.32 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/09/2017 | AbbVie, Inc. | Androgel (Drug), Synthroid | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | Regeneron Pharmaceuticals, Inc. | $202.26 | 1 |
About Dr. Scott Rasmussen, MD
Dr. Scott Rasmussen, MD is a Internal Medicine healthcare provider based in Lincoln, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013920180.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Rasmussen, MD has received a total of $1,400 in payments from pharmaceutical and medical device companies, with $202.26 received in 2022. These payments were reported across 13 transactions from 3 companies. The most common payment nature is "Travel and Lodging" ($860.27).
Practice Information
- Specialty Internal Medicine
- Location Lincoln, NE
- Active Since 08/13/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1013920180
Products in Payments
- MK-8591 (Drug) $1,184
- Androgel (Drug) $12.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Lincoln
Brock Cookman, D.o, D.O
Internal Medicine — Payments: $694,509
Dr. Ryan Martin, Md, MD
Internal Medicine — Payments: $414,185
Matthew Johnson, M.d, M.D
Internal Medicine — Payments: $307,471
Dr. Sherri Thomas, Do, DO
Internal Medicine — Payments: $100,336
Frank D'alessandro, Md Inc, MD INC
Internal Medicine — Payments: $86,860
Peter Gallagher, M.d, M.D
Internal Medicine — Payments: $83,162